Maresin1 regulates neutrophil recruitment and IL-10 expression in Aspergillus fumigatus keratitis.
Animals
Anti-Inflammatory Agents
/ therapeutic use
Aspergillosis
/ drug therapy
Aspergillus fumigatus
/ physiology
Chemokine CXCL1
/ metabolism
Disease Models, Animal
Docosahexaenoic Acids
/ therapeutic use
Humans
Interleukin-10
/ metabolism
Keratitis
/ drug therapy
Mice
Mice, Inbred C57BL
Neutrophil Infiltration
/ drug effects
Neutrophils
/ drug effects
RAW 264.7 Cells
Aspergillus fumigatus
Cytokines
Fungal keratitis
Inflammatory cells
Maresin1
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
08
10
2018
revised:
19
12
2018
accepted:
22
01
2019
pubmed:
29
1
2019
medline:
19
7
2019
entrez:
29
1
2019
Statut:
ppublish
Résumé
Maresin1, a lipid mediator derived from polyunsaturated fatty acids, has been shown to suppress the inflammatory response in various inflammatory diseases. However, its effects in fungal keratitis are still uncertain. In this study, we investigated the role of maresin1 (MaR1) in Aspergillus fumigatus keratitis of the eye in a mouse model. Mouse corneas were infected with A. fumigatus by corneal intrastromal injection. Two hours after infection, maresin1 (5 ng/5 μl) was delivered by subconjunctival injection. Then, topical administration of maresin1 (5 ng/3 μl) was applied to mouse corneas twice a day from day 1 to day 5. The development of FK lesions, the production of chemokines, the production of inflammation cytokines and the levels of p-GSK3β were measured via slit-lamp biomicroscope, quantitative polymerase chain reaction (qRT-PCR) and western blot. The presence of neutrophils in the cornea was detected by immunofluorescence staining and myeloperoxidase. The effect of maresin1 on A. fumigatus stimulated mouse macrophage RAW264.7 cells was assessed via PCR and Western blot. In our study, administration of maresin1 reduced the severity of fungal keratitis with infiltration of fewer neutrophils and reduced levels of the chemokine CXCL1, while the anti-inflammatory cytokines such as IL-10 were enhanced compared with the PBS group. Additionally, in vitro studies showed that treatment with maresin1 inhibited the production of the chemokine CXCL1 and enhanced IL-10 levels in A. fumigatus stimulated RAW264.7 mouse macrophages. Moreover, levels of p-GSK3β increased after maresin1 treatment in A. fumigatus stimulated RAW264.7 cells. Taken together, these findings demonstrate that treatment with maresin1 moderates corneal inflammation through reducing neutrophil recruitment and levels of the chemokine CXCL1 and enhancing the anti-inflammatory cytokine IL-10 in A. fumigatus keratitis. Additionally, maresin1 alters levels of GSK3β phosphorylation to regulate CXCL1 and IL-10 expression in response to A. fumigatus infection. Topical administration of maresin1 may emerge as a novel anti-inflammatory molecule and has a protective role in A. fumigatus keratitis.
Identifiants
pubmed: 30690344
pii: S1567-5769(18)30838-5
doi: 10.1016/j.intimp.2019.01.032
pii:
doi:
Substances chimiques
7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
0
Anti-Inflammatory Agents
0
Chemokine CXCL1
0
Interleukin-10
130068-27-8
Docosahexaenoic Acids
25167-62-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-108Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.